<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Domschke, Katharina</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Neurobiologic and Psychopharmacologic Solutions for the Treatment of Depression</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7-9</style></pages><abstract><style  face="normal" font="default" size="100%">Antidepressant treatment response is dependent upon numerous individual factors, such as gender, age, disease severity, symptom type, comorbidities, and genetic factors. New advances in pharmacogenetics, neurosurgical intervention, and medications may hold the key to improving treatment response in patients with refractory depression.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>